Central Nervous System Lymphoma

Oncology·MeSH: Hematologic Diseases

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

14 drugs in development·6 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
Ibrutinib	Merck & Co., Inc. (MRK)
PD -1/PD-L1 monoclonal antibody	ENANTA PHARMACEUTICALS INC (ENTA)
tirabrutinib	Deciphera Pharmaceuticals, Inc. (DCPH)
tirabrutinib	Eton Pharmaceuticals, Inc. (ETON)
tirabrutinib	West Pharmaceutical Services Inc. (WST)

Phase 2(1)

Drug	Company
Orelabrutinib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(8)

Drug	Company
Cytarabine	Black Diamond Therapeutics, Inc. (BDTX)
Ibrutinib	Black Diamond Therapeutics, Inc. (BDTX)
Isavuconazole	ENANTA PHARMACEUTICALS INC (ENTA)
Isavuconazole	Black Diamond Therapeutics, Inc. (BDTX)
TEDD	Black Diamond Therapeutics, Inc. (BDTX)
TEDD	ENANTA PHARMACEUTICALS INC (ENTA)
TEDDI	ENANTA PHARMACEUTICALS INC (ENTA)
TEDDI	Black Diamond Therapeutics, Inc. (BDTX)

BioSniper tracks 14 drugs in development for Central Nervous System Lymphoma across 6 companies.

There are 4 clinical trials targeting Central Nervous System Lymphoma tracked by BioSniper.

The estimated prevalence of Central Nervous System Lymphoma is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.